AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36967714 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma from vaccinees
Number of subjects: 0
Study 36967714 — intervention group
Group type: COMPARATOR
Intervention: Convalescent plasma from REMAP-CAP and Argentinian trials
Number of subjects: 0
Study 36967840 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcoronary stem cell transfer
Number of subjects: 22
Study 36967843 — intervention group
Group type: EXPERIMENTAL
Intervention: Wharton jelly multipotent stem cells (WJMSCs) transcoronary transfer
Number of subjects: 10
Study 36967843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 36968218 — intervention group
Group type: EXPERIMENTAL
Intervention: Local ablation + sorafenib
Number of subjects: 104
Study 36968218 — intervention group
Group type: COMPARATOR
Intervention: Local ablation + placebo
Number of subjects: 104
Study 36968554 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-in-1 Abacavir/Lamivudine/Lopinavir/Ritonavir (30/15/40/10 mg) fixed-dose combination of granules in a capsule
Number of subjects: 36
Study 36968629 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control (systolic BP < 120 mm·Hg)
Number of subjects: 3310
Study 36968629 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure control (systolic BP < 140 mm·Hg)
Number of subjects: 3310
Study 36968637 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety symptoms
Number of subjects: 0
Study 36968637 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping mechanisms
Number of subjects: 0
Study 36968652 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-dose PHEN/TPM (7.5 mg/46 mg)
Number of subjects: 223
Study 36968652 — intervention group
Group type: EXPERIMENTAL
Intervention: Top-dose PHEN/TPM (15 mg/92 mg)
Number of subjects: 223
Study 36968652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study 36968754 — intervention group
Group type: EXPERIMENTAL
Intervention: Step guided multicomponent interprofessional intervention program (group therapy, daily training, individual sessions)
Number of subjects: 41
Study 36968754 — intervention group
Group type: EXPERIMENTAL
Intervention: Step guided multicomponent interprofessional intervention program
Number of subjects: 41
Study 36969023 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately hypo-fractionated radiotherapy (60Gy in 24 fractions) concurrent with S-1
Number of subjects: 58
Study 36969063 — intervention group
Group type: EXPERIMENTAL
Intervention: TDM-guided dosing of alectinib (intervention arm A)
Number of subjects: 0
Study 36969063 — intervention group
Group type: COMPARATOR
Intervention: Fixed dosing of alectinib 600 mg taken twice daily with food (control arm B)
Number of subjects: 0
Study 36969244 — intervention group
Group type: EXPERIMENTAL
Intervention: JE-YF17D vaccination followed by YF17D challenge
Number of subjects: 70
Study 36969244 — intervention group
Group type: EXPERIMENTAL
Intervention: YF17D vaccination followed by JE-YF17D challenge
Number of subjects: 70
Study 36969244 — intervention group
Group type: COMPARATOR
Intervention: Inactivated JEV vaccine followed by YF17D challenge
Number of subjects: 70
Study 36969338 — intervention group
Group type: EXPERIMENTAL
Intervention: Napabucasin plus nab-paclitaxel with gemcitabine
Number of subjects: 1134
Study 36969338 — intervention group
Group type: COMPARATOR
Intervention: Nab-paclitaxel with gemcitabine (control)
Number of subjects: 1134
Study 36969389 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided psychological Internet-delivered intervention
Number of subjects: 0
Study 36969390 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone cognitive behavioral therapy (CBT) for body dysmorphic disorder, specific dosage and duration not mentioned.
Number of subjects: 0
Study 36969546 — intervention group
Group type: COMPARATOR
Intervention: Education attention control
Number of subjects: 27
Study 36969546 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment (manualized, family-tailored education and problem-solving adherence intervention)
Number of subjects: 27
Study 36969704 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest tertile of 8-isoprostane
Number of subjects: 0
Study 36969704 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,3-dinor-8-F
Number of subjects: 0
Study 36969704 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary isoprostanes
Number of subjects: 0
Study 36969747 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA monitoring during first-line treatment
Number of subjects: 132
Study 36969745 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic inhibition of SHP2
Number of subjects: 0
Study 36969745 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor cell-specific depletion of SHP2
Number of subjects: 0
Study 36969889 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg TMF
Number of subjects: 48
Study 36969889 — intervention group
Group type: COMPARATOR
Intervention: 300 mg TDF
Number of subjects: 48
Study 36969982 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile interventions plus nicotine replacement therapy sampling (NRT-S)
Number of subjects: 664
Study 36969982 — intervention group
Group type: COMPARATOR
Intervention: Regular text messages regarding general health
Number of subjects: 664
Study 36970054 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Nab-Paclitaxel/Xeloda (GAX) in Combination With Cisplatin and Irinotecan (GAX-CI)
Number of subjects: 12
Study 36970056 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-931 50 mg once daily for 14 days in 21-day cycles (schedule A)
Number of subjects: 80
Study 36970056 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-931 (schedule B)
Number of subjects: 80
Study 36970056 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-931 50 mg once daily days 1-14 in 21-day cycles
Number of subjects: 80
Study 36970056 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-931
Number of subjects: 80
Study 36970055 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus nab-paclitaxel
Number of subjects: 76
Study 36970055 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus nab-paclitaxel
Number of subjects: 76
Study 36970055 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel plus gemcitabine
Number of subjects: 76
Study 36970275 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous ketamine infusion
Number of subjects: 0
Study 36970545 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week O-RAGT program in combination with usual care physiotherapy
Number of subjects: 34
Study 36970545 — intervention group
Group type: COMPARATOR
Intervention: Usual care physiotherapy only
Number of subjects: 34
Study 36970876 — intervention group
Group type: EXPERIMENTAL
Intervention: Vevorisertib monotherapy
Number of subjects: 78
Study 36970876 — intervention group
Group type: EXPERIMENTAL
Intervention: Vevorisertib plus paclitaxel
Number of subjects: 78
Study 36970876 — intervention group
Group type: EXPERIMENTAL
Intervention: Vevorisertib plus fulvestrant
Number of subjects: 78
Study 36970971 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab 200 mg plus Pegaspargase 2500 U/m, combined with Anlotinib and radiotherapy
Number of subjects: 0
Study 36971108 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitally delivered Acceptance and Commitment Therapy (ACT) for chronic pain, specific dosage and duration not mentioned.
Number of subjects: 0
Study 36971108 — intervention group
Group type: COMPARATOR
Intervention: Not applicable, as no control group is mentioned in the abstract.
Number of subjects: 0
Study 36971225 — intervention group
Group type: EXPERIMENTAL
Intervention: Refugees diagnosed with PTSD
Number of subjects: 0
Study 36971225 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 36971560 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumacaftor-ivacaftor treatment
Number of subjects: 75
Study 36971688 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined behavioural and lifestyle interventions (dietary modification and increased physical activity)
Number of subjects: 610
Study 36971688 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined behavioural and lifestyle interventions
Number of subjects: 610
Study 36971690 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 16302
Study 36971735 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Relapse Prevention (MBRP)
Number of subjects: 182
Study 36971735 — intervention group
Group type: COMPARATOR
Intervention: Relapse Prevention (RP)
Number of subjects: 182
Study 36971771 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab low dose (LD [75/150 mg])
Number of subjects: 320
Study 36971771 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab high dose (HD [75/150/300 mg])
Number of subjects: 320
Study 36971771 — intervention group
Group type: EXPERIMENTAL
Intervention: Any secukinumab LD
Number of subjects: 320
Study 36971771 — intervention group
Group type: EXPERIMENTAL
Intervention: Any secukinumab HD
Number of subjects: 320
Study 36971771 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab (both LD and HD)
Number of subjects: 320
Study 36971816 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative leak testing group (IOLT)
Number of subjects: 148
Study 36971816 — intervention group
Group type: COMPARATOR
Intervention: No intraoperative leak testing group (NIOLT)
Number of subjects: 148
Study 36971978 — intervention group
Group type: EXPERIMENTAL
Intervention: Online survey measuring pregnancy preferences, perceived CKD severity, perception of pregnancy risk, pregnancy intention, distress, social support, illness perceptions, and quality of life.
Number of subjects: 315
Study 36971978 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical data extracted from local databases.
Number of subjects: 315
Study 36972022 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus paclitaxel and carboplatin
Number of subjects: 816
Study 36972022 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus paclitaxel and carboplatin
Number of subjects: 816
Study 36972026 — intervention group
Group type: EXPERIMENTAL
Intervention: Dostarlimab (500 mg) plus carboplatin and paclitaxel
Number of subjects: 494
Study 36972026 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus carboplatin and paclitaxel
Number of subjects: 494
Study 36972049 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Cognitive Behavioral Therapy for Insomnia (DCBT-I)
Number of subjects: 82
Study 36972049 — intervention group
Group type: COMPARATOR
Intervention: Sleep Education
Number of subjects: 82
Study 36972088 — intervention group
Group type: EXPERIMENTAL
Intervention: Discordant-positive participants (perceived health change more positive than actual)
Number of subjects: 0
Study 36972088 — intervention group
Group type: EXPERIMENTAL
Intervention: Discordant-negative participants (perceived health change worse than actual)
Number of subjects: 0
Study 36972088 — intervention group
Group type: COMPARATOR
Intervention: Concordant participants (perceived health change aligned with actual)
Number of subjects: 0
Study 36972105 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based therapist tutorial on Prolonged Grief Disorder Therapy (PGDT)
Number of subjects: 406
Study 36972117 — intervention group
Group type: EXPERIMENTAL
Intervention: Ohnut (phallus length reducer)
Number of subjects: 40
Study 36972117 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (no intervention)
Number of subjects: 40
Study 36972117 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal insert (substudy)
Number of subjects: 40
Study 36972140 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-only resection (Group-S)
Number of subjects: 24
Study 36972140 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-plus-orbicularis muscle resection (Group-M)
Number of subjects: 24
Study 36972208 — intervention group
Group type: EXPERIMENTAL
Intervention: GeneXpert HIV-1 assay
Number of subjects: 242
Study 36972208 — intervention group
Group type: COMPARATOR
Intervention: Central laboratory testing (standard of care)
Number of subjects: 242
Study 36972231 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacutaneous fibrolysis (DF)
Number of subjects: 86
Study 36972279 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic-based memory-encoding strategy
Number of subjects: 39
Study 36972279 — intervention group
Group type: COMPARATOR
Intervention: Cognitive stimulation
Number of subjects: 39
Study 36972491 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP + Bortezomib
Number of subjects: 0
Study 36972491 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 0
Study 36972639 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group 1 (tip position in subclavian or axillary vein)
Number of subjects: 330
Study 36972639 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group 2 (tip position not specified)
Number of subjects: 330
Study 36972639 — intervention group
Group type: COMPARATOR
Intervention: Control Group (tip position not specified)
Number of subjects: 330
Study 36972694 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (20-mg/kg single oral dose)
Number of subjects: 21832
Study 36972694 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equivalent volume)
Number of subjects: 21832
Study 36972738 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel Stent
Number of subjects: 0
Study 36972738 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 0
Study 36972796 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting antivirals (DAAs) treatment for hepatitis C virus (HCV), specific dosage and duration not mentioned.
Number of subjects: 0
Study 36972800 — intervention group
Group type: EXPERIMENTAL
Intervention: 26 g of freeze-dried wild blueberry (WBB) powder (302 mg anthocyanins)
Number of subjects: 61
Study 36972800 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo (0 mg anthocyanins)
Number of subjects: 61
Study 36972814 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular intervention (EVI)
Number of subjects: 4475
Study 36972814 — intervention group
Group type: COMPARATOR
Intervention: Bypass surgery
Number of subjects: 4475
Study 36972814 — intervention group
Group type: COMPARATOR
Intervention: Hybrid surgery
Number of subjects: 4475
Study 36972835 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital insertion of Foley catheter balloon
Number of subjects: 100
Study 36972835 — intervention group
Group type: COMPARATOR
Intervention: Speculum-guided insertion of Foley catheter balloon
Number of subjects: 100
Study 36972920 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy with stent removal (CEASR)
Number of subjects: 31
Study 36972920 — intervention group
Group type: COMPARATOR
Intervention: Repeated carotid angioplasty and stenting (rePTA/S)
Number of subjects: 31
Study 36972920 — intervention group
Group type: COMPARATOR
Intervention: Both groups (CEASR and rePTA/S)
Number of subjects: 31
Study 36972964 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune and metabolic whole-blood markers in patients with sepsis
Number of subjects: 0
Study 36972964 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated lipidomics and RNASeq transcriptomics analyses
Number of subjects: 0
Study 36972964 — intervention group
Group type: COMPARATOR
Intervention: Clinical phenotyping and blood culture test results
Number of subjects: 0
Study 36972972 — intervention group
Group type: EXPERIMENTAL
Intervention: KDIGO-based AKI care bundle
Number of subjects: 1302
Study 36972972 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 1302
Study 36973007 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions relieving dyspnea
Number of subjects: 0
Study 36973055 — intervention group
Group type: EXPERIMENTAL
Intervention: Health TAPESTRY intervention (home visit from volunteers, care plan by interprofessional team)
Number of subjects: 599
Study 36973055 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 599
Study 36973055 — intervention group
Group type: EXPERIMENTAL
Intervention: Health TAPESTRY intervention
Number of subjects: 599
Study 36973127 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-ROBOSCORE (difficulty score for robotic pancreatoduodenectomy)
Number of subjects: 1184
Study 36973127 — intervention group
Group type: COMPARATOR
Intervention: Robotic pancreatoduodenectomy
Number of subjects: 1184
Study 36973578 — intervention group
Group type: EXPERIMENTAL
Intervention: Attribution of GWI to behavior (e.g., diet and exercise)
Number of subjects: 262
Study 36973578 — intervention group
Group type: COMPARATOR
Intervention: Attribution of GWI to deployment, physical, or psychological causes
Number of subjects: 262
Study 36973667 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus add-on person-centred care through telephone support and a digital platform
Number of subjects: 220
Study 36973667 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 220
Study 36973671 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartile 4 (waist:height ratio 0.62)
Number of subjects: 541
Study 36973671 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher waist:height ratio
Number of subjects: 541
Study 36973688 — intervention group
Group type: EXPERIMENTAL
Intervention: verum Electroacupuncture (vEA) - ten weekly treatment visits at 13 therapeutic acupuncture points
Number of subjects: 64
Study 36973688 — intervention group
Group type: COMPARATOR
Intervention: sham Electroacupuncture (sEA) - weekly treatment visits at 7 non-disease-related acupuncture points
Number of subjects: 64
Study 36973732 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS women with sexual dysfunction (SxD)
Number of subjects: 51
Study 36973732 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS women without sexual dysfunction (SxD)
Number of subjects: 51
Study 36973732 — intervention group
Group type: COMPARATOR
Intervention: Controls (women without IBS)
Number of subjects: 51
Study 36973741 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab + MTX
Number of subjects: 685
Study 36973741 — intervention group
Group type: COMPARATOR
Intervention: golimumab without MTX
Number of subjects: 685
Study 36973743 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional Assist Ventilation (PAV+)
Number of subjects: 0
Study 36973743 — intervention group
Group type: COMPARATOR
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 0
Study 36973774 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Music Engagement (AME)
Number of subjects: 228
Study 36973774 — intervention group
Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 228
Study 36973815 — intervention group
Group type: EXPERIMENTAL
Intervention: PASC (surgical patient safety checklist)
Number of subjects: 428
Study 36973815 — intervention group
Group type: COMPARATOR
Intervention: Not using PASC (due to various reasons)
Number of subjects: 428
Study 36973954 — intervention group
Group type: EXPERIMENTAL
Intervention: rilonacept 320 mg followed by weekly doses of 160 mg for 6 weeks
Number of subjects: 20
Study 36973954 — intervention group
Group type: EXPERIMENTAL
Intervention: rilonacept
Number of subjects: 20
Study 36973954 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 36974122 — intervention group
Group type: EXPERIMENTAL
Intervention: TBI patients
Number of subjects: 160
Study 36974270 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of the internet for health information and eHealth literacy
Number of subjects: 2924
Study 36974462 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin microbiota from high-risk patients
Number of subjects: 90
Study 36974462 — intervention group
Group type: EXPERIMENTAL
Intervention: Toll-like receptor 4 (TLR4) antagonists
Number of subjects: 90
Study 36974462 — intervention group
Group type: EXPERIMENTAL
Intervention: Gram-negative bacteria
Number of subjects: 90
Study 36974462 — intervention group
Group type: EXPERIMENTAL
Intervention: Metagenome sequencing analyses
Number of subjects: 90
Study 36974462 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased amino acid metabolites
Number of subjects: 90
Study 36974462 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic resistance genes
Number of subjects: 90
Study 36974574 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon ion radiotherapy in combination with immune checkpoint inhibitors (pembrolizumab)
Number of subjects: 27
Study 36974638 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin and allopurinol in combination (Group 4)
Number of subjects: 800
Study 36974638 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin (Group 3)
Number of subjects: 800
Study 36974638 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (Group 2)
Number of subjects: 800
Study 36974638 — intervention group
Group type: COMPARATOR
Intervention: N-acetyl cysteine and saline (Control Group 1)
Number of subjects: 800
Study 36974653 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised multi-nut oral food challenge (OFC) using multi-nut butter
Number of subjects: 212
Study 36974653 — intervention group
Group type: COMPARATOR
Intervention: Standard care (home introduction of individual tree nuts)
Number of subjects: 212
Study 36974680 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PCI angina assessment using the Seattle Angina Questionnaire (SAQ-7) and European quality of life-5 dimension-5 level (EQ-5D-5L) questionnaires.
Number of subjects: 230
Study 36974680 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary physiology assessments before and after stenting.
Number of subjects: 230
Study 36974714 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative renal insufficiency (RI) group
Number of subjects: 502281
Study 36974714 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative renal insufficiency (RI) group with current dialysis, eGFR ≤ 30 ml/min/1.73 m² or concomitant anemia
Number of subjects: 502281
Study 36974735 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet intervention
Number of subjects: 611
Study 36974887 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative measurement of highly fluorescent immature platelet fraction (H-IPF)
Number of subjects: 391
Study 36974988 — intervention group
Group type: EXPERIMENTAL
Intervention: AS01-adjuvanted vaccine containing four surface proteins from non-typable
Number of subjects: 0
Study 36975019 — intervention group
Group type: EXPERIMENTAL
Intervention: More intense blood pressure control
Number of subjects: 22885